FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer. PMID 41092328 · N Engl J Med · 2025-Oct-16 The report is a randomized trial in oncology with a primary time-to-event endpoint, but it compares surgical procedures (sentinel-lymph-node biopsy vs. lymphadenectomy) and does not involve a drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vitamin D Supplementation and Testosterone Levels in Breast Cancer Survivors. PMID 41155322 · Int J Mol Sci · 2025-Oct-15 The study is an oncology RCT with a drug intervention and human subjects, but it does not meet the core requirement of a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoint is a continuous biomarker (testosterone levels), which is a safety or secondary endpoint, not a time-to-event outcome. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk-stratified breast cancer screening - a protocol for a non-blinded randomised trial. PMID 41133331 · Dan Med J · 2025-Oct-15 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of goal-directed fluid therapy on the postoperative outcome in head and neck cancer surgery: study protocol for a randomized controlled trial. PMID 41094585 · Trials · 2025-Oct-15 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial. PMID 41094532 · Trials · 2025-Oct-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3). PMID 41093345 · BMJ Open · 2025-Oct-15 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma. PMID 40668662 · Blood Adv · 2025-Oct-14 The study is excluded because the primary/key endpoint is not a time-to-event outcome (it is based on objective response rates and tumor size changes), and the analysis is a cross-trial comparison, not a single randomized trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol for a multi-site randomized clinical trial of an intervention program to promote self-management among head and neck cancer survivors with lymphedema and fibrosis [PROMISE trial]. PMID 41084063 · Trials · 2025-Oct-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Sedating with volatile anaesthetics for COVID-19 and non-COVID-19 acute hypoxaemic respiratory failure patients in ICU (SAVE-ICU): protocol for a randomised clinical trial. PMID 41083292 · BMJ Open · 2025-Oct-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study. PMID 41077611 · Signal Transduct Target Ther · 2025-Oct-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study. PMID 41043438 · Cancer Cell · 2025-Oct-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. PMID 41074934 · J Neurol · 2025-Oct-11 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study. PMID 41075778 · Med · 2025-Oct-10 The record is for an oncology, human, randomized trial with a drug intervention (relacorilant + nab-paclitaxel vs. nab-paclitaxel) and a primary time-to-event endpoint (PFS, OS). It is an original result report. However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata (title, abstract, publication types, MeSH), making the 'phase3_or_definitive' criterion unverifiable. Therefore, overall eligibility is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). PMID 40902132 · J Clin Oncol · 2025-Oct-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The effect of positive psychology interventions on job satisfaction work engagement and withdrawal intentions among remote working cancer survivors. PMID 41068189 · Sci Rep · 2025-Oct-09 The study is a randomized trial in cancer survivors, but it evaluates a positive psychology intervention (non-drug) on occupational/psychological outcomes, not a drug intervention on a time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. PMID 40768751 · Blood · 2025-Oct-09 The record describes a randomized, oncology trial with a drug intervention and original results, but lacks an explicit Phase III/IIIb designation and does not specify a time-to-event endpoint in the provided abstract, making it ineligible under the strict criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cold snare endoscopic resection for large colon polyps: a randomised trial. PMID 40393701 · Gut · 2025-Oct-08 The study is a randomized trial of endoscopic procedures for benign colon polyps, not a drug intervention trial for human malignant neoplasm with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial. PMID 41053831 · J Transl Med · 2025-Oct-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. PMID 41052882 · J Immunother Cancer · 2025-Oct-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. PMID 41046179 · Eur Urol · 2025-Oct-03 The record describes a randomized trial in oncology with a drug intervention and time-to-event endpoints, but the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided abstract or metadata, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection. PMID 41042339 · Langenbecks Arch Surg · 2025-Oct-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The effectiveness of adding Braun anastomosis to standard Child reconstruction to reduce delayed gastric emptying after pancreatoduodenectomy (REMBRANDT): study protocol for a multicentre randomised-controlled trial. PMID 41039614 · Trials · 2025-Oct-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Paleolithic diet fraction and score in post hoc data analysis of a randomized controlled trial with lifestyle interventions for abdominal obesity. PMID 41039470 · BMC Nutr · 2025-Oct-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of a Translatable Web-Based Intervention for Increasing Physical Activity Among Cancer Survivors: Pilot Randomized Trial. PMID 41037739 · JMIR Cancer · 2025-Oct-02 The study is a pilot randomized trial of a web-based physical activity intervention for cancer survivors. It is oncology-related and human, but it lacks a drug intervention and a time-to-event efficacy endpoint. The phase is not specified as definitive (III/IIIb or II/III), and the primary outcome is feasibility/physical activity, not survival or time-to-event. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma. PMID 41123892 · JAMA Netw Open · 2025-Oct-01 This is a secondary, retrospective cohort analysis evaluating racial disparities across multiple historical GOG RCTs. It is not a primary report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention as the key element. The phase of the underlying trials is not explicitly stated in the provided metadata, and the report does not focus on a specific drug intervention, making it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preserved Cognitive Function After Statin Administration During Cancer Treatment With Doxorubicin: A Secondary Analysis of a Randomized Clinical Trial. PMID 41118164 · JAMA Netw Open · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points. PMID 41066125 · JAMA Netw Open · 2025-Oct-01 The study is an independent decision-analytic model estimating outcomes of a planned screening trial, not a clinical trial report. It does not involve a drug intervention, and its outcomes (late-stage incidence reductions, mortality reductions over fixed periods) are not time-to-event endpoints in the required sense. The trial phase is not specified. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. PMID 41034823 · BMC Cancer · 2025-Oct-01 The study meets most criteria but fails the critical time-to-event endpoint requirement. The primary efficacy outcome is the proportion of patients without nausea in the overall phase (0-120h), which is a categorical response rate, not a time-to-event measure like OS, PFS, or similar. No Kaplan-Meier curves or hazard ratios are mentioned. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma. PMID 41021440 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A prospective study of serum folate levels in patients with solid tumors treated with olaparib. PMID 41014151 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of a whole food plant-based dietary intervention on cancer progression and inflammatory markers. PMID 40973844 · Oncologist · 2025-Oct-01 The study is a randomized trial in metastatic breast cancer reporting original results, but it lacks a primary/key secondary time-to-event efficacy endpoint (only biomarker changes are reported), the intervention is dietary (not a drug), and it does not explicitly establish a Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. PMID 40973474 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. PMID 40876952 · J Nucl Med · 2025-Oct-01 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI). PMID 40876084 · Eur J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer. PMID 40850317 · Eur J Cancer · 2025-Oct-01 The record describes a randomized trial of a non-drug supportive care intervention (patient navigation with symptom monitoring) for advanced lung cancer. While it reports time-to-event endpoints (PFS, OS) as secondary outcomes, it does not meet the core criteria: (1) the trial phase is not specified as Phase III/IIIb or Phase II/III (sample size of 150 suggests an earlier phase), and (2) the intervention is not a drug-containing intervention. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment. PMID 40818318 · Eur J Cancer · 2025-Oct-01 The record describes a secondary/prognostic analysis of a randomized trial (CRITICS), not the primary or definitive efficacy report. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. While oncology, human, randomized, drug intervention, and time-to-event endpoints are present, the study is not an original primary result of a definitive-phase trial comparing interventions for efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. PMID 40810951 · JAMA Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial. PMID 40773220 · JAMA Oncol · 2025-Oct-01 The study is an eligible Phase 3 randomized oncology trial with a drug intervention and original primary results, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is the incidence of severe acute radiation oral mucositis (grade ≥3 AROM), which is a categorical toxicity/outcome measure, not a time-to-event measure like OS, PFS, DFS, etc. There is no mention of Kaplan-Meier analysis or hazard ratio. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial. PMID 40736443 · Clin Cancer Res · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders. PMID 40705465 · J Clin Invest · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. PMID 40579995 · Neuro Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of single-incision laparoscopic surgery for colorectal cancer, a single-center, open-label, randomized controlled trial. PMID 40549445 · Int J Surg · 2025-Oct-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial. PMID 40490846 · Int J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomised trial on treatment of vaginal high-grade squamous intraepithelial lesion: Self-administered vaginal imiquimod and laser vaporisation. PMID 40454918 · Int J Cancer · 2025-Oct-01 Eligibility criteria require an original Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). While the record describes a randomized trial with a drug intervention (imiquimod) in an oncology setting (vaginal HSIL), it fails on two key grounds: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III; the abstract and metadata do not specify a phase, and the deterministic review correctly flags 'phase3: false'. 2) The primary efficacy endpoint is histological regression rate (a categorical outcome), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier or HR. The abstract does not mention any time-to-event analysis or survival curves. Therefore, it does not meet the mandatory criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of Outcomes of Microsurgical Breast Reconstruction after Premastectomy and Postmastectomy Radiation Therapy. PMID 40366003 · J Am Coll Surg · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial. PMID 40354950 · Int J Radiat Oncol Biol Phys · 2025-Oct-01 The record describes a Phase III randomized trial (RAPIDO) with a drug intervention, but the primary endpoints are acute and late radiation-related toxicity and treatment compliance, analyzed as binary outcomes with logistic regression. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier curves or hazard ratios. Therefore, it is ineligible for this KM digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A machine learning approach for radiation pneumonitis prediction in elderly esophageal cancer patients by integrating baseline computed tomography radiomics, dosiomics, and clinical characteristics. PMID 41333544 · Phys Imaging Radiat Oncol · 2025-Oct This is a secondary predictive modeling study based on a Phase III trial, not a primary report of the trial's efficacy results. The endpoint is a toxicity (radiation pneumonitis), not a time-to-event efficacy endpoint (OS, PFS, etc.). No drug intervention is described. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Low-Dose Colchicine in Patients With Type 2 Diabetes With Recent Myocardial Infarction in the Colchicine Cardiovascular Outcome Trial (COLCOT): A Systematic Review. PMID 41322854 · Cureus · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase. PMID 41181851 · EClinicalMedicine · 2025-Oct The record describes a randomized Phase III trial of umbilical cord-derived mesenchymal stromal cells for recessive dystrophic epidermolysis bullosa, a non-oncologic genetic disorder. While it is a randomized trial with original results, it does not meet the core eligibility criteria: it is not an oncology study, it involves a cell therapy (not a conventional drug), and the primary endpoint (EBDASI) is not a time-to-event efficacy measure. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial. PMID 41181826 · EClinicalMedicine · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |